<DOC>
	<DOC>NCT00878618</DOC>
	<brief_summary>The aims of this study are to evaluate the pharmacokinetics, safety and tolerability of the oral doses of the extended-release test- and reference formulations of AZD0837 in healthy volunteers both in fasting and fed conditions.</brief_summary>
	<brief_title>Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837</brief_title>
	<detailed_description />
	<criteria>Healthy subject aged between 18 to 45 years inclusive Body mass index (BMI) between 19 to 30 kg/m2 inclusive Body weight between 50 to 100 kg inclusive Women must be either postmenopausal, permanently sterilised or, if of childbearing potential, must have a negative pregnancy test before intake of study medication and use a reliable form of contraception before and during participation in the study. Significant illness (including ongoing or history of liver disease), trauma or surgical procedures from 2 weeks before the preentry visit until the first administration of Investigational Product Clinical significant abnormalities in clinical chemistry, haematology or urinalysis result including positive result on screening tests for serum hepatitis B surface antigen, hepatitis C antibody or HIV or positive FHb result preentry History of bleeding disturbance (including extensive menstrual bleedings) or thrombotic disorder Clinically significant medical history, as judged by the investigator, including psychiatric disorders or severe allergies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Healthy volunteers</keyword>
</DOC>